A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer Journal Article
| Authors: | Suidan, R. S.; St. Clair, C. M.; Lee, S. J.; Barlin, J. N.; Long Roche, K. C.; Tanner, E. J.; Sonoda, Y.; Barakat, R. R.; Zivanovic, O.; Chi, D. S. |
| Article Title: | A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer |
| Abstract: | To compare survival outcomes for patients with advanced epithelial ovarian cancer (EOC) who received primary intravenous/intraperitoneal (IV/IP) chemotherapy to those who received IV followed by consolidation (treatment given to patients in remission) IP chemotherapy. Data were analyzed and compared for all patients with stage III-IV EOC who underwent optimal primary cytoreduction (residual disease ≤ 1 cm) followed by cisplatin-based consolidation IP chemotherapy (1/2001-12/2005) or primary IV/IP chemotherapy (1/2005-7/2011). We identified 224 patients; 62 (28%) received IV followed by consolidation IP chemotherapy and 162 (72%) received primary IV/IP chemotherapy. The primary IP group had significantly more patients with serous tumors. The consolidation IP group had a significantly greater median preoperative platelet count, CA-125, and amount of ascites. There were no differences in residual disease at the end of cytoreduction between both groups. The median progression-free survival (PFS) was greater for the primary IP group; however, this did not reach statistical significance (23.7 months vs 19.7 months; HR 0.78; 95% CI, 0.57-1.06; p=0.11). The median overall survival (OS) was significantly greater for the primary IP group (78.8 months vs 57.5 months; HR 0.56; 95% CI, 0.38-0.83; p=0.004). On multivariate analysis, after adjusting for confounders, the difference in PFS was not significant (HR 0.78; 95% CI, 0.56-1.11; p=0.17), while the difference in OS remained significant (HR 0.59; 95% CI, 0.39-0.89; p=0.01). In our study, primary IV/IP chemotherapy was associated with improved OS compared to IV followed by consolidation IP chemotherapy in patients with optimally cytoreduced advanced EOC. Copyright © 2014 Elsevier Inc. All rights reserved. |
| Keywords: | adult; aged; aged, 80 and over; disease-free survival; middle aged; survival rate; retrospective studies; young adult; overall survival; mortality; antineoplastic agents; comparative study; disease free survival; antineoplastic agent; neoplasm; ovarian cancer; ovarian neoplasms; ovary cancer; pathology; retrospective study; ovary tumor; infusions, intravenous; infusion; infusions, parenteral; intraperitoneal chemotherapy; intravenous drug administration; neoplasms, glandular and epithelial; progression-free survival; very elderly; humans; human; female; article; consolidation intraperitoneal chemotherapy |
| Journal Title: | Gynecologic Oncology |
| Volume: | 134 |
| Issue: | 3 |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2014-09-01 |
| Start Page: | 468 |
| End Page: | 472 |
| Language: | English |
| DOI: | 10.1016/j.ygyno.2014.07.090 |
| PUBMED: | 25042672 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 1 December 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work